Serena Di Cosimo - JoVE Visualize

Showing results (101-110 of 152) with videos related to

Pageof 16

Sort By:

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2019

Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO TrialSerena Di Cosimo, Valentina Appierto, Sara Pizzamiglio, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009

Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II studyJavier Cortes, Serena Di Cosimo, Miguel A Climent, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2003

Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamidePaola Papaldo, Massimo Lopez, Enrico Cortesi, et al.

NPJ Breast Cancer|November 26, 2021

Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trialTomás Pascual, Mafalda Oliveira, Patricia Villagrasa, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2014

Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trialSerena Di Cosimo, Sriram Sathyanarayanan, Johanna C Bendell, et al.

Cancer|October 19, 2018

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trialsMatteo Lambertini, Samuel Martel, Christine Campbell, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2006

Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?Paola Papaldo, Gianluigi Ferretti, Serena Di Cosimo, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2013

Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trialHatem A Azim, Dominique Agbor-Tarh, Ian Bradbury, et al.

Cancers|November 9, 2024

From Real-World Data to Causally Interpretable Models: A Bayesian Network to Predict Cardiovascular Diseases in Adolescents and Young Adults with Breast CancerAlice Bernasconi, Alessio Zanga, Peter J F Lucas, et al.

Frontiers in Oncology|April 4, 2022

mRNA-COVID19 Vaccination Can Be Considered Safe and Tolerable for Frail PatientsMaria Teresa Lupo-Stanghellini, Serena Di Cosimo, Massimo Costantini, et al.

Pageof 16

Showing results (101-110 of 152) with videos related to

Sort By:

Pageof 16

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2019

Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO TrialSerena Di Cosimo, Valentina Appierto, Sara Pizzamiglio, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009

Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II studyJavier Cortes, Serena Di Cosimo, Miguel A Climent, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2003

Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamidePaola Papaldo, Massimo Lopez, Enrico Cortesi, et al.

NPJ Breast Cancer|November 26, 2021

Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trialTomás Pascual, Mafalda Oliveira, Patricia Villagrasa, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2014

Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trialSerena Di Cosimo, Sriram Sathyanarayanan, Johanna C Bendell, et al.

Cancer|October 19, 2018

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trialsMatteo Lambertini, Samuel Martel, Christine Campbell, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2006

Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?Paola Papaldo, Gianluigi Ferretti, Serena Di Cosimo, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2013

Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trialHatem A Azim, Dominique Agbor-Tarh, Ian Bradbury, et al.

Cancers|November 9, 2024

From Real-World Data to Causally Interpretable Models: A Bayesian Network to Predict Cardiovascular Diseases in Adolescents and Young Adults with Breast CancerAlice Bernasconi, Alessio Zanga, Peter J F Lucas, et al.

Frontiers in Oncology|April 4, 2022

mRNA-COVID19 Vaccination Can Be Considered Safe and Tolerable for Frail PatientsMaria Teresa Lupo-Stanghellini, Serena Di Cosimo, Massimo Costantini, et al.

Pageof 16